Literature DB >> 16441437

Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8.

Eva Pericolini1, Elio Cenci, Claudia Monari, Magdia De Jesus, Francesco Bistoni, Arturo Casadevall, Anna Vecchiarelli.   

Abstract

The major virulence factor of Cryptococcus neoformans is its polysaccharide capsule composed of glucuronoxylomannan (GXM), galactoxylomannan (GalXM) and mannoproteins. A variety of immunomodulating activities have been described for GXM and mannoproteins but little is known about possible interactions of GalXM with the immune system. In the present article, we investigate the effect of purified soluble GalXM on human T lymphocytes. The results indicate that, GalXM (i) can affect selected immune responses; (ii) causes significant impairment of T cell proliferation and increases interferon-gamma and interleukin-10 production; and (iii) induces apoptosis of T lymphocytes through activation of caspase-8 that terminates with fragmentation of DNA. These results are the first to suggest a role for GalXM in C. neoformans virulence by demonstrating that it can target human T cells, and that it may impair the development of an effective specific T cell response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16441437     DOI: 10.1111/j.1462-5822.2005.00619.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  38 in total

Review 1.  Immune response and immunotherapy to Cryptococcus infections.

Authors:  Qing Zhou; William J Murphy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Induction of death receptor CD95 and co-stimulatory molecules CD80 and CD86 by meningococcal capsular polysaccharide-loaded vaccine nanoparticles.

Authors:  Ruhi V Ubale; Rikhav P Gala; Susu M Zughaier; Martin J D'Souza
Journal:  AAPS J       Date:  2014-07-01       Impact factor: 4.009

3.  Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

4.  Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.

Authors:  Leonardo Nimrichter; Susana Frases; Leonardo P Cinelli; Nathan B Viana; Antonio Nakouzi; Luiz R Travassos; Arturo Casadevall; Marcio L Rodrigues
Journal:  Eukaryot Cell       Date:  2007-06-15

5.  Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.

Authors:  Magdia De Jesus; André Moraes Nicola; Marcio L Rodrigues; Guilhem Janbon; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2008-10-24

6.  Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences.

Authors:  Susana Frases; Leonardo Nimrichter; Nathan B Viana; Antonio Nakouzi; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2007-12-21

7.  Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides.

Authors:  J Stacey Klutts; Tamara L Doering
Journal:  J Biol Chem       Date:  2008-03-17       Impact factor: 5.157

8.  Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage.

Authors:  Eva Pericolini; Elena Gabrielli; Giovanni Bistoni; Elio Cenci; Stefano Perito; Siu-Kei Chow; Francesca Riuzzi; Rosario Donato; Arturo Casadevall; Anna Vecchiarelli
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

Review 9.  How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans.

Authors:  Tamara Lea Doering
Journal:  Annu Rev Microbiol       Date:  2009       Impact factor: 15.500

10.  Surfactant protein D increases phagocytosis of hypocapsular Cryptococcus neoformans by murine macrophages and enhances fungal survival.

Authors:  Scarlett Geunes-Boyer; Timothy N Oliver; Guilhem Janbon; Jennifer K Lodge; Joseph Heitman; John R Perfect; Jo Rae Wright
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.